/ /

Cheryl Guttman Krader
Robotic vs. open RP: Experts react to first randomized trial
We spoke to Gerald L. Andriole, MD, Michael Koch, MD, Herbert Lepor, MD, Mani Menon, MD, and Joel Nelson, MD, about the highly anticipated study findings.
Study: PCa genomic test reduces decisional conflict
For men with high-risk pathology at radical prostatectomy, exposure to results of a genomic test that classifies 5-year risk of metastasis reduces decisional conflict, according to findings of a prospective study presented at the American Society of Clinical Oncology annual meeting in Chicago.
Cognitive, mood effects characterized for PCa therapies
An ongoing phase II trial investigating abiraterone acetate (ZYTIGA) and enzalutamide (XTANDI) as treatment for men with chemotherapy-naïve metastatic castrate-resistant prostate cancer is aiming to characterize the effects of these targeted hormonal therapies on cognition and mood.
Oral agent improves survival in advanced RCC patients
Once-daily treatment with cabozantinib (CABOMETYX), an oral tyrosine kinase inhibitor, significantly improves overall survival as well as progression-free survival and objective responses rates compared with everolimus (Afinitor) in previously treated patients with advanced renal cell carcinoma, according to final results from the phase III METEOR trial.
Residency applicants most value operative experience
Applicants to urology residency programs have clear ideas about what they are seeking in a training program and a good understanding of the factors influencing their rankings, according to the findings of a survey presented at the AUA annual meeting San Diego.
Bladder Ca linked to risk of second primary cancer
Among survivors of the most common types of cancer, bladder cancer survivors have the highest risk for developing a second primary cancer, according to a recent study.
Low concordance with NCCN surveillance guide seen
Concordance with National Cancer Comprehensive Network recommendations about follow-up during active surveillance for low-risk prostate cancer is generally low across urology practices in Michigan, reported researchers from the Michigan Urological Surgery Improvement Collaborative at the AUA annual meeting in San Diego.
Adjuvant chemo well tolerated in high-risk PCa patients
A Veterans Administration Cooperative Study investigating chemotherapy after prostatectomy for high-risk prostate cancer was underpowered to show a statistically significant benefit of early adjuvant chemotherapy versus observation as the standard of care in the primary endpoint analysis of progression-free survival.
Bladder Ca guide provides risk-stratified framework
A recently released guideline on diagnosis and treatment of nonmuscle-invasive bladder cancer from the AUA and the Society of Urologic Oncology provides practitioners with a risk-stratified clinical framework to aid treatment decisions and surveillance strategies, said Sam S. Chang, MD, MBA.
How number of Peyronie’s Tx cycles affects outcomes
In a study of intralesional collagenase clostridium histolyticum, mean curvature was reduced most dramatically after the first cycle, researchers reported.

Poll

View Results